12-06-2021 | Exenatide | News
A phase 3 cardiovascular safety trial finds exenatide delivered from an osmotic mini-pump to be noninferior to placebo.
08-04-2021 | Exenatide | News
Click through for more information on this expanded indication
03-04-2020 | Exenatide | News
Short-acting exenatide “does not seem to have a future” as a standard adjunct treatment in people with type 1 diabetes, say the MAG1C investigators.
08-19-2019 | GLP-1 agonists | Highlight | News
Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.
12-08-2017 | Cardiovascular outcomes | News
A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.
09-15-2017 | Exenatide | EASD 2017 | News
The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.
09-13-2017 | GLP-1 agonists | EASD 2017 | News
One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.
09-13-2017 | Exenatide | EASD 2017 | News
The 52-week findings of the DURATION-8 trial show durable glycemic control with the combination of exenatide and dapagliflozin in patients with type 2 diabetes.